Background {#Sec1}
==========

Complicated urinary tract infection (cUTI) is associated with significant morbidity and increased health care costs, particularly as resistance to first-line antimicrobial agents has become widespread \[[@CR1], [@CR2]\]. Hospitalization for cUTIs caused by Gram-negative bacteria (typically Enterobacteriaceae such as *Escherichia coli*) in the United States increased by approximately 50% from 2000 to 2009, whereas the incidence of infections caused by extended-spectrum β-lactamase (ESBL)--positive organisms increased by approximately 300% in the same time period \[[@CR3]\].

Fluoroquinolones such as levofloxacin have historically been an attractive therapy for cUTI (including pyelonephritis) because of their high drug concentrations in the urine and their demonstrated clinical efficacy \[[@CR4]\]. However, their future usefulness is threatened by alarmingly high rates of fluoroquinolone resistance, often occurring in combination with other resistance mechanisms including ESBL production. A surveillance study of 24 US hospitals found that less than 70% of non-ESBL--producing isolates of *E. coli* were susceptible to ciprofloxacin or levofloxacin, and this number fell to less than 10% for ESBL-producing strains \[[@CR5]\]. The challenge of fluoroquinolone resistance is even greater in other regions of the world \[[@CR6]\]. Resistance to fluoroquinolones can occur through a combination of point mutations in the target gyrase and topoisomerase genes, plasmid-mediated mechanisms (eg, qnr), and upregulated efflux of the drug \[[@CR7], [@CR8]\]. The spread of these resistance mechanisms has been facilitated by their strong association with the worldwide pandemic clone of *E. coli*, ST-131 \[[@CR9]\].

In the clinical management of cUTI, it remains common practice to treat patients empirically, at least during the 2- to 3-day time period required to obtain standard culture results \[[@CR10], [@CR11]\]. As resistance increases, recommendations either to avoid empiric use of fluoroquinolones or to use these antibacterials judiciously based on local surveillance data are becoming more prevalent \[[@CR12], [@CR13]\]. Guidance directed toward uncomplicated urinary tract infections, published by the Infectious Diseases Society of America and the European Society for Clinical Microbiology and Infectious Diseases, supports a 3-day course of fluoroquinolone therapy, but only in regions where the resistance rate is lower than 10% \[[@CR14]\].

Previous clinical studies have concluded that high urinary tract concentrations of fluoroquinolones are sufficient to allow successful outcomes for nonsusceptible isolates. One large *post hoc* analysis examined a population in whom the level of fluoroquinolone resistance was relatively low (\<10%) \[[@CR15]\]. Patients received levofloxacin (750 mg intravenously) or ciprofloxacin (either 400 mg intravenously or 500 mg orally) for 10 days. Forty-two fluoroquinolone-resistant isolates (levofloxacin minimum inhibitory concentration \[MIC\] ≥8 μg/mL and ciprofloxacin MIC ≥4 μg/mL) were reported. Six isolates had levofloxacin or ciprofloxacin MICs ranging from 8 to 32 μg/mL and were eradicated with treatment, and 13 isolates with fluoroquinolone MICs \>32 μg/mL persisted. The outcomes of the remaining 23 isolates were not presented. A smaller study of a 500-mg dose of levofloxacin conducted in a setting of higher levofloxacin resistance calculated a 90% probability of microbiological eradication of Gram-negative bacilli at an MIC of 2 μg/mL. Eradication was evaluated only 2 days after therapy, however, a time when levofloxacin may still be present in the urine and suppressing the growth of organisms that could result in a different microbiological outcome after the drug has cleared \[[@CR16]\]. In vitro urinary bactericidal titer experiments demonstrated that the concentration of levofloxacin in urine following a 750-mg dose was bactericidal to *E. coli* isolates with MICs ≤32 μg/mL \[[@CR17]\].

In this exploratory analysis, we examined the clinical and microbiological outcomes of treatment with high-dose, extended-duration levofloxacin (750 mg for 7 days) by levofloxacin MIC in a large sample of patients with cUTI caused by Enterobacteriaceae in the ASPECT-cUTI phase 3 clinical trial.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

ASPECT-cUTI (ClinicalTrials.gov, [NCT01345929](https://www.clinicaltrials.gov/ct2/show/NCT01345929) and [NCT01345955](https://www.clinicaltrials.gov/ct2/show/NCT01345955)) was a large, global, phase 3 program that evaluated the efficacy and safety of ceftolozane/tazobactam versus levofloxacin for the treatment of adult hospital patients with cUTI, including pyelonephritis \[[@CR18]\]. The trials were approved by appropriate regulatory agencies and local institutional review boards (IRB) and were conducted in accordance with International Conference on Harmonisation/Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients provided written informed consent. Patients with cUTI (defined in \[[@CR18]\]) were randomly assigned 1:1 to ceftolozane/tazobactam (1.5 g intravenous every 8 h) or levofloxacin (750 mg intravenous once daily) for 7 days of therapy. Patients were included in the microbiological modified intent-to-treat (mMITT) population if they received any amount of study drug and had at least one but not more than two causative uropathogen(s) growing at ≥10^5^ CFU/mL from a study-qualifying pretreatment baseline urine specimen. The microbiologically evaluable (ME) population was the subset of the mMITT population who adhered to study procedures and had interpretable urine culture results at the test-of-cure (TOC) visit (5--9 days after the last dose of study drug).

The ASPECT-cUTI study provided data on 370 patients in the mMITT population and 327 patients in the ME population who had ≤1 isolate of Enterobacteriaceae at baseline and were treated with levofloxacin. A total of 333 Enterobacteriaceae were isolated from 327 patients in the ME population. Susceptibility data were available for 313 of these isolates.

Levofloxacin efficacy analysis {#Sec4}
------------------------------

An exploratory analysis of levofloxacin-treated patients with an Enterobacteriaceae isolate and characterized levofloxacin susceptibility from the screening visit in ASPECT-cUTI was conducted to evaluate the microbiological and clinical outcomes at the TOC and late follow-up (LFU) visits (21--42 days after the last dose of study drug). The ME population was selected for analysis to exclude patients with indeterminate outcomes. Clinical cure at the TOC visit was defined as complete resolution, substantial improvement (ie, reduction in severity of all baseline signs and symptoms), or return to premorbid signs and symptoms without the need for additional antibiotic therapy. Microbiological eradication was defined as a TOC urine culture with \<10^4^ CFU/mL of the baseline uropathogen. The per-pathogen microbiological and clinical outcomes at the TOC visit were stratified by levofloxacin MIC of each baseline infecting organism. Clinical outcomes for patients who were classified as clinical cures at the TOC visit and who returned for the LFU visit were classified as sustained, indeterminate, or relapsed based on the sustained resolution or relapse in clinical signs and symptoms of cUTI that were absent at the TOC visit. Relative proportions of each of these categories were examined for patients whose infections were microbiologically eradicated versus those who had persisting positive cultures at the TOC visit.

Susceptibility testing {#Sec5}
----------------------

Susceptibility and quality control testing of study isolates was performed by ICON Laboratories (Farmingdale, NY) in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. Quality control testing was performed concurrent with testing of clinical study isolates. Interpretation of susceptibility test results and acceptable quality control ranges were based on CLSI document M100-S22 \[[@CR19]\]. Study isolates initially characterized as levofloxacin-resistant (MIC \>4 μg/mL) \[[@CR19]\] were retested to determine the levofloxacin MIC end point up to 256 μg/mL.

Statistical analysis {#Sec6}
--------------------

Descriptive statistics were used to summarize the demographics, baseline characteristics, clinical outcomes, microbiological outcomes, and genotypes of patients, and 95% confidence intervals (CIs) were calculated by the Wilson score methodology to compare the relapse rates at LFU. Statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).

Results {#Sec7}
=======

Demographics and baseline clinical characteristics of 370 levofloxacin-treated patients with ≥1 isolate each of Enterobacteriaceae identified at baseline in the mMITT population are shown in Table [1](#Tab1){ref-type="table"}. Most patients had pyelonephritis (82.7%) and most were enrolled in Europe (74.9%); 24.3% were 65 years of age or older.Table 1Characteristics of levofloxacin-treated patients with ≥1 isolate of Enterobacteriaceae identified at baseline (mMITT population)CharacteristicLevofloxacin *N* = 370Age, years Mean (SD)48.0 (20.26) Range, *n* (%)18--87  ≥ 65--\< 7547 (12.7)  ≥ 7543 (11.6)Sex, *n* (%) Male82 (22.2) Female288 (77.8)Race, *n* (%) White317 (85.7) Black or African American6 (1.6) Asian30 (8.1) Other17 (4.6)Region, *n* (%) Eastern Europe277 (74.9) Western Europe0 North America9 (2.4) South America39 (10.5) Rest of world45 (12.2)Diagnosis, *n* (%) Pyelonephritis306 (82.7) cLUTI64 (17.3)Creatinine clearance, mL/min, *n* (%) Normal (≥80)250 (67.6) Mild impairment (≥50--\< 80)92 (24.9) Moderate impairment (≥30--\< 50)27 (7.3) Severe impairment (\<30)1 (0.3)*cLUTI* complicated lower urinary tract infection, *mMITT* microbiological modified intent-to-treat, *SD* standard deviation

Clinical and microbiological outcomes of levofloxacin treatment stratified by levofloxacin MICs are listed in Table [2](#Tab2){ref-type="table"}. High rates of clinical cure (90--100%) were observed at levofloxacin MICs ≤4 μg/mL. Rates of microbiological eradication were also consistently high (\>90%) at levofloxacin MICs ≤0.06 μg/mL. However, at levofloxacin MICs \>0.06 μg/mL, a trend toward decreasing eradication rates was observed.Table 2Microbiological eradication and clinical cure following levofloxacin treatment stratified by MIC (Enterobacteriaceae isolates, ME population)Baseline levofloxacin MIC, μg/mLMicrobiological eradication, *n*/*N* (%)Clinical cure, *n*/*N* (%)≤0.0159/10 (90.0)10/10 (100)0.03120/126 (95.2)124/126 (98.4)0.0638/40 (95.0)37/40 (92.5)0.1259/11 (81.8)10/11 (90.9)0.256/8 (75.0)8/8 (100)0.514/17 (82.4)17/17 (100)15/6 (83.3)6/6 (100)21/1 (100)0/1 (0)^a^43/9 (33.3)9/9 (100)811/17 (64.7)15/17 (88.2)1620/44 (45.5)36/44 (81.8)324/13 (30.8)11/13 (84.6)641/6 (16.7)4/6 (66.7)1280/1 (0)0/1 (0)*ME* microbiologically evaluable, *MIC* minimum inhibitory concentration, *n* number of isolates assigned to an outcome of eradication or clinical cure, *N* number of isolates at each levofloxacin MICFour *E. coli* isolates were not retested to determine MIC end points and were excluded from this analysis. Five patients had 2 Enterobacteriaceae isolates identified at baseline. Four patients had a clinical response of cure, and 1 patient had a clinical response of failure. Clinical response for these patients was counted once for each isolate at its respective MIC^*a*^ This isolate was present in combination with a second isolate that had a levofloxacin MIC of 16 μg/mL; the patient's clinical response was failure

A higher percentage of patients with persistent infection at the TOC visit experienced relapse by the LFU visit than did patients whose infections were eradicated at the TOC visit (18.5% vs 1.3%; difference, 17.2%; 95% CI, 8.7--29.6%) (Table [3](#Tab3){ref-type="table"}).Table 3Impact of microbiological outcome at TOC on clinical outcome at LFU (ME population)Microbiological outcome at TOC visitClinical outcome at LFU visit% Difference in relapse between persisted and eradicated (95% CI)SustainedIndeterminateRelapseEradicated, *n*/*N* (%)225/229 (98.3)1/229 (0.4)3/229 (1.3)17.2 (8.7--29.6)Persisted, *n*/*N* (%)42/54 (77.8)2/54 (3.7)10/54 (18.5)*CI* confidence interval, *LFU* late follow-up, *ME* microbiologically evaluable, *TOC* test-of-cureFour patients had 2 Enterobacteriaceae isolates identified at baseline and a clinical response of cure at the TOC visit. These patients were counted once for this analysis by assignment to the "persisted at TOC group" if 1 isolate persisted (1 patient) and to the "eradicated at TOC group" if both isolates were eradicated (3 patients). All 4 experienced sustained response at the LFU visit

Discussion and conclusions {#Sec8}
==========================

In several recent and ongoing clinical trials in cUTI, levofloxacin has been used as the comparator against such agents as doripenem \[[@CR20]\], plazomicin ([NCT01096849](https://www.clinicaltrials.gov/ct2/show/NCT01096849)), ceftolozane/tazobactam \[[@CR18]\], and eravacycline ([NCT01978938](https://www.clinicaltrials.gov/ct2/show/NCT01978938)). A recent meta-analysis examined multiple cUTI trials before ASPECT-cUTI and identified microbiological eradication rates at the TOC visit in the microbiological intent-to-treat population of 81% for doripenem, 79% for levofloxacin, and 80.5% for imipenem-cilastatin, confirming that levofloxacin has a place in the armamentarium for cUTI \[[@CR21]\]. In an era of increasing and evolving antibiotic resistance, however, decisions about clinical usefulness must be made at the local hospital and individual patient level \[[@CR22]\].

High-dose levofloxacin treatment (750 mg once daily for 7 days) in ASPECT-cUTI resulted in clinical cure for the more than 90% of patients with Enterobacteriaceae infections who had MICs ≤4 μg/mL. Nevertheless, persistence of the baseline pathogen became more frequent as the MIC increased, with an eradication rate of \<90% observed at an MIC of only 0.125 μg/mL. A similar decrease in the microbiological eradication rate with levofloxacin treatment above a levofloxacin MIC of 0.06 μg/mL was observed during the phase 3 doripenem studies, though the total numbers of patients treated was smaller \[[@CR20]\].

The clinical significance of failure to eradicate the causative pathogen while resolving clinical symptoms is unknown, but multiple studies have shown that fluoroquinolone resistance is strongly correlated with persistence of symptoms \[[@CR23]\] and recurrence of infection \[[@CR24]\]. The results presented in this study show that, as expected, an increase in levofloxacin MIC was correlated with a decrease in microbiological eradication rate with levofloxacin treatment. Clinical cure without microbiological eradication of the causative pathogen was more likely (difference, 17.2%; 95% CI, 8.7--29.6%) to result in a relapse of cUTI at the LFU visit. The levofloxacin-resistant isolates from this study had high levofloxacin MICs that were associated with common and highly conserved fluoroquinolone resistance mechanisms, most typically point mutations in gyrA and parC (data not shown).

Pharmacokinetic/pharmacodynamic (PK/PD) targets for fluoroquinolone treatment in cUTI have been studied in depth. Typically, AUC/MIC ratios of 100 or C~max~/MIC ratios of 10 are associated with good clinical outcomes \[[@CR25]\], though 90% microbiological eradication of Gram-negative cUTI pathogens has been reported at targets as low as 31.46 and 2.74, respectively \[[@CR16]\]. Data on the pharmacokinetics of levofloxacin in either serum or urine were not obtained during ASPECT-cUTI; therefore, direct analysis of these outcomes as they relate to the levofloxacin concentration is not possible. Administration of single 750-mg doses of levofloxacin to 10 healthy adults was reported to produce AUC and C~max~ values of 93 ± 15 μg · h/mL and 7.6 ± 1.2 μg/mL in serum and 7328 ± 3237 μg · h/mL and 620 ± 324 μg/mL in urine, respectively \[[@CR17]\]. Conservatively applying the lower bound of the PK ranges and the higher PK/PD targets predicts that levofloxacin MICs of 0.5 μg/mL should be treatable in serum. In urine, the value is between 16 and 32 μg/mL, depending on whether the C~max~ or the AUC parameter is used. However, elevated MIC treatment targets based on urinary concentrations are not supported by the outcomes in this study, which is the first to examine a population with high levels of levofloxacin resistance using a stringent criterion for microbiological eradication.

In summary, these clinical data demonstrate that high-dose, extended-duration levofloxacin treatment (750 mg for 7 days) of patients with cUTIs was less likely to be successful when the MIC of the infecting organism was ≥4 μg/mL and less likely to be sustainable when the MIC was \>0.06 μg/mL.

Additional file {#Sec9}
===============

Additional file 1:List of Institutional Review Boards (IRB) and Independent Ethics Committees (IEC). (DOCX 13 kb)

CFU

:   Colony-forming unit

CI

:   Confidence interval

CLSI

:   Clinical and Laboratory Standards Institute

cUTI

:   Complicated urinary tract infection

ESBL

:   Extended-spectrum β-lactamase

LFU

:   Late follow-up

ME

:   Microbiologically evaluable

MIC

:   Minimum inhibitory concentration

mMITT

:   Microbiological modified intent-to-treat

PD

:   Pharmacodynamic

PK

:   Pharmacokinetic

TOC

:   Test-of-cure

Editorial support for this manuscript was provided by Jean Turner of PAREXEL, Hackensack, NJ, USA, and Sally Mitchell, PhD, and Sarah Utley, PhD, of ApotheCom, Yardley, PA, and was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Funding {#FPar1}
=======

This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. Employees of the study sponsor, in collaboration with the authors, were involved in the study design, data collection and analysis, decision to publish, and preparation of the manuscript.

Availability of data and materials {#FPar2}
==================================

Data generated and analyzed during this study are included in this published article; where data are not shown, they may be obtained from the corresponding author on reasonable request.

Authors' contributions {#FPar3}
======================

E.S.A. substantially contributed to the acquisition and analysis of the data, interpretation of results, drafting and critically revising the manuscript for important intellectual content, gave approval of the final version of the manuscript to be published, and agreed to be accountable for the integrity of the data and the accuracy of the work. J.A.M. substantially contributed to the interpretation of the study data, drafting and critically revising the manuscript for important intellectual content, gave approval of the final version of the manuscript to be published, and agreed to be accountable for the integrity of the data and the accuracy of the work. D.J.C. substantially contributed to the conception of the study, analysis of the data, interpretation of results, drafting and critically revising the manuscript for important intellectual content, gave approval of the final version of the manuscript to be published, and agreed to be accountable for the integrity of the data and the accuracy of the work. C.A.B. substantially contributed to the analysis of the data and interpretation of results, drafting and critically revising the manuscript for important intellectual content, gave approval of the final version of the manuscript to be published, and agreed to be accountable for the integrity of the data and the accuracy of the work. J.N.S. substantially contributed to the design and planning of the study, analysis of the data and interpretation of results, and critically revising the manuscript for important intellectual content, gave approval of the final version of the manuscript to be published, and agreed to be accountable for the integrity of the data and the accuracy of the work.

Authors' information {#FPar4}
====================

Not applicable.

Competing interests {#FPar5}
===================

J.A.M. is a current employee and E.S.A., D.J.C., C.A.B, and J.N.S. are former employees of Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

E.S.A. was working under a contract from Pro Unlimited, 7777 Glades Road, Boca Raton, FL 33434, USA, at the time of the study.

Consent for publication {#FPar6}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar7}
==========================================

The study was conducted in accordance with principles of Good Clinical Practice and the principles of the Declaration of Helsinki and was approved by the appropriate institutional review boards (IRB) and regulatory agencies. The protocol (including use of data and samples), informed consent form, and all other written documents provided to patients were reviewed and approved by the respective independent IRB (see Additional file [1](#MOESM1){ref-type="media"}) before the study began.
